Components of the gut microbiome can confer immunity against various diseases.

GBC-HpVac's new molecule GBC-R1 harnesses the beneficial potential of gastric bacteria while avoiding the risks.

A revolution in first-line treatment of allergic and inflammatory diseases is under way.


Join us.


GBC-HpVac SA responds to one of the most significant unmet needs in human medicine: allergic and inflammatory diseases, in particular asthma, both in adults and in children.

GBC-R1 is an immunomodulatory protein with strong epidemiological evidence of activity in humans against asthma and other allergic and inflammatory diseases.


In the course of her studies, Prof. Dr. Anne Müller and her team at the University of Zurich have discovered that GBC-R1 alone has a tolerogenic effect that confers protection against several inflammatory and allergic diseases.